| Remission of refractory minimal change nephrotic syndrome after basiliximab therapy. | |
| | |
MedLine Citation:
|
PMID: 19242727 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Minimal change nephrotic syndrome has been proposed to be a disorder of T cell dysfunction. It is hypothesized that a circulating factor(s) from activated T cells might alter glomerular permeability to protein. Some studies have provided evidence that up-regulation of interleukin-2 may be involved, not only in the pathophysiology of minimal change nephrotic syndrome, but also in steroid resistance. Basiliximab, an anti-interleukin-2 receptor antibody, is indicated for the prophylaxis of acute organ rejection in adults and children with kidney transplants. Clinical trials have shown that basiliximab is effective and well tolerated. We describe here a pediatric patient who continuously had massive proteinuria and hypoalbuminemia for 5 years, despite pulse therapy with methylprednisolone and cyclophosphamide and prolonged oral treatment with cyclosporine and mizoribine. He had experienced several disease- and treatment-associated complications, such as bacterial infections, indirect inguinal hernias, and cataracts. After he had been given a single dose of basiliximab, he achieved complete remission of proteinuria and then discontinued all immunosuppressant treatment. |
| | |
Authors:
|
Sung-Shin Park; Won-Ho Hahn; Sung-Do Kim; Byoung-Soo Cho |
Related Documents
:
|
19904897 - Nephrotic syndrome in adults: diagnosis and management. 8636807 - Increased urinary nitrite excretion in children with minimal change nephrotic syndrome. 9035177 - Two cases of nephrotic syndrome and tertian malaria in south-eastern anatolia. 9061417 - Childhood renal diseases in saudi arabia. a clinicopathological study of 167 cases. 19904897 - Nephrotic syndrome in adults: diagnosis and management. 6419457 - Bilateral congenital absence of the abducens nerve. |
Publication Detail:
|
Type: Case Reports; Journal Article Date: 2009-02-26 |
Journal Detail:
|
Title: Pediatric nephrology (Berlin, Germany) Volume: 24 ISSN: 1432-198X ISO Abbreviation: Pediatr. Nephrol. Publication Date: 2009 Jul |
Date Detail:
|
Created Date: 2009-06-01 Completed Date: 2009-08-18 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8708728 Medline TA: Pediatr Nephrol Country: Germany |
Other Details:
|
Languages: eng Pagination: 1403-7 Citation Subset: IM |
Affiliation:
|
Department of Pediatrics, East West Kidney Diseases Research Institute, Kyung-Hee University, Hoegi-dong, Dongdaemun-gu, Seoul, 130-702, Korea. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Anti-Inflammatory Agents
/
therapeutic use Antibodies, Monoclonal / therapeutic use* Child, Preschool Cyclophosphamide / therapeutic use Cyclosporine / therapeutic use Humans Immunosuppressive Agents / therapeutic use* Male Methylprednisolone / therapeutic use Nephrosis, Lipoid / drug therapy*, physiopathology Recombinant Fusion Proteins / therapeutic use* Ribonucleosides / therapeutic use |
| Chemical | |
Reg. No./Substance:
|
0/Anti-Inflammatory Agents; 0/Antibodies, Monoclonal; 0/Immunosuppressive Agents; 0/Recombinant Fusion Proteins; 0/Ribonucleosides; 0/basiliximab; 50-18-0/Cyclophosphamide; 50924-49-7/bredinin; 59865-13-3/Cyclosporine; 83-43-2/Methylprednisolone |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Patterns of tandem repetition in plant whole genome assemblies.
Next Document: Albuminuria and insulin resistance in children with biopsy proven non-alcoholic fatty liver disease.